Billion-Dollar Deal With a Vision! How Merck Aims to Revolutionize Lung Medicine With Verona Pharma!

Merck (MRK) digs deep into its pockets – and shows strategic foresight. With the planned acquisition of the respiratory disease-focused biotech company Verona Pharma for around 10 billion USD, the pharmaceutical giant not only secures an innovative COPD medication with Ohtuvayre®, but also strategically strengthens its portfolio in a high-growth segment. The transaction is part of a long-term plan to reposition itself for the period after the patent expiration of its top-selling drug Keytruda – and could prove to be a smart investment in the...